Please login to the form below

Not currently logged in

J&J sales up 8.3 per cent

Johnson & Johnson has reported total sales of $16.60bn for the second quarter of 2011, with strong international pharma growth countering a decline in US consumer products due in part to several recalls

Johnson & Johnson (J&J) has reported total sales of $16.60bn for the second quarter of 2011, an improvement of 8.3 per cent on 2010's performance.

Net profit for the company was down, however, decreasing from $3.45bn for Q2 2010 to $2.78bn for the same period in 2011. This year's figure was affected by an after-tax charge of $549m representing restructuring by Cordis Corporation, as well as litigation charges of $363m and a $54m cost for the recall of the DePuy ASRTM Hip.

The company's strongest area of growth was in pharmaceutical products sold outside the US. J&J made $2.99bn in the region, an increase of 22.6 per cent from 2010.

Behind this growth were recent product launches and approvals, including psoriasis treatment Stelara (ustekinumab); prostate cancer drug Zytiga (abiraterone acetate) and Invega Sustenna (paliperidone palmitate) for schizophrenia.

The strong international performance helped vounter a downturn in sales for the company's US consumer segment, with revenues down 8.5 per cent. J&J has faced several recalls and suspensions in the past year relating to products produced at its McNeil Consumer Healthcare facility in Fort Washington, Pennsylvania.

The company's half-year figures saw net earnings decrease too, with the company making $6.25bn for the first six months of 2011 compared to $7.98bn in 2010.

Sales for the period were up by 5.8 per cent, however, totalling $32.77bn.

19th July 2011


Featured jobs

Subscribe to our email news alerts


Add my company

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...